NCT06290765撤回4 期
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera - A Randomized Open Label Global Multicenter Study (PARADIGM-PV)
PharmaEssentia0 个研究点目标入组 70 人开始时间: 2026年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- 入组人数
- 70
- 主要终点
- The proportion of patients whose Hct is maintained without phlebotomy eligibility from Week 20 through Week 32.
研究概览
简要总结
This is a randomized, open-label, multicenter, two-arm study to assess the efficacy and safety of ropeginterferon alfa-2b for patients with PV. The entire study period is 60 weeks, including a main treatment phase (32 weeks), an extension treatment phase (24 weeks), and a safety follow-up phase (four weeks). However, the study may be extended for additional period of treatment after Week 60 pending the primary endpoint analysis at Week 32. Approximately 70 patients with PV will be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 59 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years at the time of informed consent (or other age required by local regulations);
- •PV according to the World Health Organization (WHO) 2016 or 2022 Criteria;
- •At least 3 phlebotomies within 24 weeks or at least 5 phlebotomies within 52 weeks prior to screening due to inadequate control of Hct value;
- •Have the following hematological values immediately prior to randomization at baseline:
- •Hematocrit <45%, and
- •WBC ≥4× 109/L, and
- •Platelets ≥100 × 109/L;
- •Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or
- •Patients receiving cytoreductive therapy must be on a stable dose or minimal dose adjustments for at least 24 weeks before screening and with no planned dose change;
- •Patients who are not receiving cytoreductive therapy must have been discontinued from any prior cytoreductive therapy for at least 24 weeks before screening and have recovered from any adverse events;
- •Females of childbearing potential, as well as all women < 2 years after the onset of menopause, must agree to use an acceptable form of birth control until 60 days following the last dose of the study drug;
- •Written informed consent obtained from the patient or the patient's legal representative, and ability for the patient to comply with the study requirements.
排除标准
- •Patients requiring phlebotomy at Hct levels ˂45% according to Investigator judgement;
- •Clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein thrombosis) or PV-related bleeding within 2 months prior to randomization;
- •Post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) (Tefferi et al 2013, Barosi et al 2008);
- •Contraindication to pegylated interferon or its excipients;
- •known resistance or intolerance to interferon based therapies, as judged by Investigator;
- •Documented autoimmune disease (e.g., thyroid dysfunction, idiopathic thrombocytopenic purpura (ITP), scleroderma, psoriasis, or any arthritis of autoimmune origin). Patients with well-managed thyroid disease by oral hormonal replacement therapy could be enrolled;
- •Pulmonary infiltrates, pneumonia, and pneumonitis at screening that, in the Investigator's opinion, would jeopardize the safety or compliance with the protocol;
- •Infections with systemic manifestations, e.g., bacterial, fungal, or human immunodeficiency virus (HIV), except inactive carriers of hepatitis B (HBV) and/or hepatitis C (HCV) at screening; inactive HBV carrier is defined as the presence of HBsAg and anti-Hepatitis B e-antigen (anti-HBe) antibody, HBV DNA ˂2000 IU/ml, and normal ALT (Invernizz et al 2016); inactive HCV carrier is defined as the presence of HCV RNA but has normal ALT or with no clinically significant symptom as judged by investigator;
- •Any investigational drug less than 6 weeks prior to randomization or not recovered from the effects of prior administration of any investigational agent;
- •History or presence of depression requiring treatment with antidepressant;
- •Previous suicide attempts or at any risk of suicide at screening, in the judgement of the Investigator;
- •Any significant morbidity or abnormality which may interfere with the study participation;
- •Pregnant or lactating females;
- •History of alcohol abuse or drug abuse within the last year;
- •Evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension);
- •Significant liver (AST or ALT > 2.5 times ULN) or renal disease (creatinine > 2 mg/ml);
- •History of major organ transplantation;
- •History or presence of clinically significant neurologic diseases, e.g., uncontrolled severe seizure disorder;
- •History of malignant disease, including solid tumors and hematological malignancies (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years.
研究组 & 干预措施
Ropeginterferon alfa-2b group
Experimental
Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), target optimal dose of 500 µg.
干预措施: Phlebotomy and aspirin (Procedure)
Control group
Other
Patients will continuously receive the same therapy as s/he received for PV indication prior to screening.
干预措施: Phlebotomy and aspirin (Procedure)
Ropeginterferon alfa-2b group
Experimental
Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), target optimal dose of 500 µg.
干预措施: Ropeginterferon alfa-2b (Drug)
结局指标
主要结局
The proportion of patients whose Hct is maintained without phlebotomy eligibility from Week 20 through Week 32.
时间窗: From Week 20 through Week 32
Phlebotomy eligibility is defined as either: a confirmed Hct ≥45% that is at least 3% higher than the baseline Hct, a confirmed Hct ≥48%, OR a confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline.
次要结局
未报告次要终点
研究者
相似试验
招募中
2 期
Ropeginterferon Alfa 2b for Early MyelofibrosisPrimary Myelofibrosis, Prefibrotic StageMyelofibrosisNCT04988815The University of Hong Kong50
招募中
2 期
Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk MyelofibrosisPre-fibrotic MyelofibrosisNCT05731245National Taiwan University Hospital50
已完成
2 期
Clinical study for investigating Ropeginterferon alfa-2b in Japanese Polycythemia Vera PatientsJPRN-jRCT2080225099PharmaEssentia Japan K.K.29
Unknown
3 期
HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon TherapyChronic Hepatitis C Infection in HIV Infected PersonsHIV InfectionsNCT00215839Hepatitis Resource Network
已完成
3 期
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.COVID-19NCT05770466National Taiwan University Hospital134